Medpace Posts 3Q EPS of $4.84
MEDP sits 77% above its 52-week low of $373 on elevated volume (3.4× avg).
Summary
Medpace reported third-quarter EPS of $4.84, with net income of $137.5M and revenue of $716M, up 8.5%. The company also launched a $1B buyback and guided fiscal 2026 revenue to $2.84B-$2.86B and EPS to $17.97-$18.32. The stock sits near its 52-week high of $677.90, so the bar is high and any softness in the full release will matter. Context: Q2 showed 17% revenue growth and a record backlog, but the company also disclosed securities litigation tied to its book-to-bill ratio, and insiders including Chairman/CEO August Troendle have been heavy sellers, with roughly $125 million sold over six weeks per the late-September 13D/A.
At the time of this announcement, MEDP was trading at $661.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.5B. The 52-week trading range was $373.00 to $677.90. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.